Literature DB >> 31547920

Endogenous Specialized Proresolving Mediator Profiles in a Novel Experimental Model of Lymphatic Obstruction and Intestinal Inflammation in African Green Monkeys.

Felix Becker1, Emily Romero2, Jason Goetzmann2, Dana L Hasselschwert2, Beth Dray3, John Vanchiere4, Jane Fontenot2, J Winny Yun5, Paul C Norris6, Luke White5, Melany Musso2, Charles N Serhan6, J Steven Alexander7, Felicity N E Gavins8.   

Abstract

Changes in the intestinal lymphatic vascular system, such as lymphatic obstruction, are characteristic features of inflammatory bowel diseases. The lymphatic vasculature forms a conduit to enable resolution of inflammation; this process is driven by specialized endogenous proresolving mediators (SPMs). To evaluate contributions of lymphatic obstruction to intestinal inflammation and to study profiles of SPMs, we generated a novel animal model of lymphatic obstruction using African green monkeys. Follow-up studies were performed at 7, 21, and 61 days. Inflammation was determined by histology. Luminex assays were performed to evaluate chemokine and cytokine levels. In addition, lipid mediator metabololipidomic profiling was performed to identify SPMs. After 7 days, lymphatic obstruction resulted in a localized inflammatory state, paralleled by an increase in inflammatory chemokines and cytokines, which were found to be up-regulated after 7 days but returned to baseline after 21 and 61 days. At the same time, a distinct pattern of SPMs was profiled, with an increase for D-series resolvins, protectins, maresins, and lipoxins at 61 days. These results indicate that intestinal lymphatic obstruction can lead to an acute inflammatory state, accompanied by an increase in proinflammatory mediators, followed by a phase of resolution, paralleled by an increase and decrease of respective SPMs.
Copyright © 2019 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31547920      PMCID: PMC6880773          DOI: 10.1016/j.ajpath.2019.05.013

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  86 in total

Review 1.  The lymphatic vasculature in disease.

Authors:  Kari Alitalo
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

2.  Obstructive lymphopathy.

Authors:  J I Burn
Journal:  Ann R Coll Surg Engl       Date:  1968-02       Impact factor: 1.891

3.  Platelet activation receptor CLEC-2 regulates blood/lymphatic vessel separation by inhibiting proliferation, migration, and tube formation of lymphatic endothelial cells.

Authors:  Makoto Osada; Osamu Inoue; Guo Ding; Toshiaki Shirai; Hirotake Ichise; Kazuyoshi Hirayama; Katsuhiro Takano; Yutaka Yatomi; Masanori Hirashima; Hideki Fujii; Katsue Suzuki-Inoue; Yukio Ozaki
Journal:  J Biol Chem       Date:  2012-05-03       Impact factor: 5.157

4.  Epidemiology and natural history of inflammatory bowel diseases.

Authors:  Jacques Cosnes; Corinne Gower-Rousseau; Philippe Seksik; Antoine Cortot
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

5.  Lipoxin B4 regulates human monocyte/neutrophil adherence and motility: design of stable lipoxin B4 analogs with increased biologic activity.

Authors:  J F Maddox; S P Colgan; C B Clish; N A Petasis; V V Fokin; C N Serhan
Journal:  FASEB J       Date:  1998-04       Impact factor: 5.191

6.  Dietary cholesterol promotes adipocyte hypertrophy and adipose tissue inflammation in visceral, but not in subcutaneous, fat in monkeys.

Authors:  Soonkyu Chung; Helen Cuffe; Stephanie M Marshall; Allison L McDaniel; Jung-Heun Ha; Kylie Kavanagh; Cynthia Hong; Peter Tontonoz; Ryan E Temel; John S Parks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-06-26       Impact factor: 8.311

7.  Lipoxin biosynthesis in inflammatory bowel disease.

Authors:  Martin J Mangino; Lionel Brounts; Bruce Harms; Charles Heise
Journal:  Prostaglandins Other Lipid Mediat       Date:  2005-12-27       Impact factor: 3.072

8.  An Infectious Pig Model of Crohn's Disease.

Authors:  Herbert J Van Kruiningen
Journal:  Inflamm Bowel Dis       Date:  2016-09       Impact factor: 5.325

Review 9.  Pro-resolving lipid mediators are leads for resolution physiology.

Authors:  Charles N Serhan
Journal:  Nature       Date:  2014-06-05       Impact factor: 49.962

10.  Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis.

Authors:  Linda Vong; Jose G P Ferraz; Neil Dufton; Remo Panaccione; Paul L Beck; Philip M Sherman; Mauro Perretti; John L Wallace
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

View more
  4 in total

1.  Ileitis-associated tertiary lymphoid organs arise at lymphatic valves and impede mesenteric lymph flow in response to tumor necrosis factor.

Authors:  Rafael S Czepielewski; Emma C Erlich; Emily J Onufer; Shannon Young; Brian T Saunders; Yong-Hyun Han; Mary Wohltmann; Peter L Wang; Ki-Wook Kim; Shashi Kumar; Chyi-Song Hsieh; Joshua P Scallan; Ying Yang; Bernd H Zinselmeyer; Michael J Davis; Gwendalyn J Randolph
Journal:  Immunity       Date:  2021-11-16       Impact factor: 31.745

2.  Are EPA and DHA Derivatives Involved in IBD Remission?

Authors:  Justyna Kikut; Arleta Drozd; Małgorzata Mokrzycka; Urszula Grzybowska-Chlebowczyk; Maciej Ziętek; Małgorzata Szczuko
Journal:  J Clin Med       Date:  2022-04-24       Impact factor: 4.964

3.  Resolvin D1 Decreases Severity of Streptozotocin-Induced Type 1 Diabetes Mellitus by Enhancing BDNF Levels, Reducing Oxidative Stress, and Suppressing Inflammation.

Authors:  Siresha Bathina; Undurti N Das
Journal:  Int J Mol Sci       Date:  2021-02-03       Impact factor: 5.923

Review 4.  Specialized Pro-Resolving Mediators and the Lymphatic System.

Authors:  Jamie D Kraft; Robert Blomgran; Iben Lundgaard; Marianne Quiding-Järbrink; Jonathan S Bromberg; Emma Börgeson
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.